Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review
Open Access
- 23 February 2025
- journal article
- review article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (2) , 447-465
Abstract
Introduction Fenfluramine (FFA) represents the latest therapeutic option approved for seizure management in Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) for patients aged ≥ 2 years. This article provides expert guidance for optimizing FFA therapy to support clinical decision-making in these populations. Methods A panel of Spanish experts specialized in developmental epileptic encephalopathies (DEEs) has developed practical recommendations for the clinical use of FFA, focusing on key aspects of FFA management: mechanism of action, pharmacokinetics including drug interactions, titration, efficacy, safety and tolerability, contraindications, and considerations for its broader application in DEEs. The methodology adopted in this project was an expert-opinion, evidence-based approach. Results The panel issued targeted recommendations, including a modified titration strategy slower than the product guidelines, adjusted for possible antiseizure concomitant medications, and management of other concomitant treatments. Key efficacy indicators, such as reductions in seizure frequency and severity of the most disabling seizures, were emphasized as core measures for treatment evaluation. Periodic assessments of non-seizure outcomes and daily life activities are recommended during follow-up to comprehensively capture treatment outcomes. The panel noted that their clinical observations align with positive findings from clinical trials, suggesting a potential role for FFA in other DEEs, tailored to individual electroclinical and etiological profiles. Conclusion This article presents expert practical recommendations for the management and treatment optimization of FFA in patients with DEEs, supporting clinicians in achieving improved patient outcomes.Keywords
Funding Information
- UCB Spain
This publication has 39 references indexed in Scilit:
- Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorderEpilepsia, 2021
- Sleep and Epilepsy: a Focused Review of Pathophysiology, Clinical Syndromes, Co-morbidities, and TherapyNeurotherapeutics, 2021
- Executive Functions and Attention in Childhood Epilepsies: A Neuropsychological Hallmark of Dysfunction?Journal of the International Neuropsychological Society, 2020
- Dravet Syndrome: A Review of Current ManagementPediatric Neurology, 2020
- Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive RegimensJAMA Neurology, 2020
- Deciphering the concepts behind “Epileptic encephalopathy” and “Developmental and epileptic encephalopathy”European Journal of Paediatric Neurology, 2020
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trialThe Lancet, 2019
- A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjectsInt. Journal of Clinical Pharmacology and Therapeutics, 2019
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and TerminologyEpilepsia, 2017
- Cognitive characterization of children with Dravet syndrome: A neurodevelopmental perspectiveChild Neuropsychology, 2014